|
|
Blood, 1 October 2006, Vol. 108, No. 7, pp. 2435-2437.
Prepublished online as a Blood First Edition Paper on June 13, 2006; DOI 10.1182/blood-2006-04-018259.
 Previous Article | Table of Contents | Next Article 
RED CELLS
Brief report
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott,
Mike A. Scott,
Peter J. Campbell, and
Anthony R. Green
From the Department of Haematology, Cambridge Institute for Medical Research; and the Department of Haematology, Addenbrooke's National Health Service (NHS) Trust, Cambridge, United Kingdom.
An acquired V617F JAK2 mutation occurs in patients with polycythemia vera (PV) or essential thrombocythemia (ET). In a proportion of V617F-positive patients, mitotic recombination produces mutation-homozygous cells that come to predominate with time. However, the prevalence of homozygosity is unclear, as previous reports studied mixed populations of wild-type, V617F-heterozygous, and V617F-homozygous mutant cells. We therefore analyzed 1766 individual hematopoietic colonies from 34 patients with PV or ET in whom granulocyte sequencing demonstrated that the mutant peak did not predominate. V617F-positive erythroid burst-forming units (BFU-Es) were more frequent in patients with PV compared with patients with ET (P = .022) and, strikingly, V617F-homozygous BFU-Es were detected in all 17 patients with PV, but in none of the patients with ET (P < .001). Moreover, mutation-homozygous cells were present in 2 patients with ET after polycythemic transformation. These results demonstrate that V617F-homozygous erythroid progenitors are present in most patients with PV but occur rarely in those with ET.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
From 1 to 2 mutated JAK2: the road from ET to PV
- Stéphane Giraudier and William Vainchenker
Blood 2006 108: 2140-2141.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
P. A. Beer, P. J. Campbell, L. M. Scott, A. J. Bench, W. N. Erber, D. Bareford, B. S. Wilkins, J. T. Reilly, H. C. Hasselbalch, R. Bowman, et al.
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Blood,
July 1, 2008;
112(1):
141 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Kiladjian, F. Cervantes, F. W. G. Leebeek, C. Marzac, B. Cassinat, S. Chevret, D. Cazals-Hatem, A. Plessier, J.-C. Garcia-Pagan, S. D. Murad, et al.
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
Blood,
May 15, 2008;
111(10):
4922 - 4929.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Blood,
May 15, 2008;
111(10):
5109 - 5117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Levine
JAK2V617F: you can't have too much.
Blood,
April 15, 2008;
111(8):
3913 - 3913.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tiedt, H. Hao-Shen, M. A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller, and R. C. Skoda
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Blood,
April 15, 2008;
111(8):
3931 - 3940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Li, R. Kralovics, G. De Libero, A. Theocharides, H. Gisslinger, and R. C. Skoda
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Blood,
April 1, 2008;
111(7):
3863 - 3866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Wilkins, W. N. Erber, D. Bareford, G. Buck, K. Wheatley, C. L. East, B. Paul, C. N. Harrison, A. R. Green, and P. J. Campbell
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
Blood,
January 1, 2008;
111(1):
60 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Percy, L. M. Scott, W. N. Erber, C. N. Harrison, J. T. Reilly, F. G.C. Jones, A. R. Green, and M. F. McMullin
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels
Haematologica,
December 1, 2007;
92(12):
1607 - 1614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani, T. L. Lasho, C. Finke, R. A. Mesa, W. J. Hogan, R. P. Ketterling, D. G. Gilliland, and A. Tefferi
Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes
Stem Cells,
September 1, 2007;
25(9):
2358 - 2362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dupont, A. Masse, C. James, I. Teyssandier, Y. Lecluse, F. Larbret, V. Ugo, P. Saulnier, S. Koscielny, J. P. Le Couedic, et al.
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
Blood,
August 1, 2007;
110(3):
1013 - 1021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L Basquiera, F. Fassetta, N. Soria, J. M. Barral, B. Ricchi, and J. J Garcia
Accuracy of leukocyte alkaline phosphatase score to predict JAK2 V617F mutation
Haematologica,
May 1, 2007;
92(5):
704 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, M. F. McMullin, C. N. Harrison, et al.
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
N. Engl. J. Med.,
February 1, 2007;
356(5):
459 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Skoda
The Genetic Basis of Myeloproliferative Disorders
Hematology,
January 1, 2007;
2007(1):
1 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Campbell and A. R. Green
The Myeloproliferative Disorders
N. Engl. J. Med.,
December 7, 2006;
355(23):
2452 - 2466.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Levine and G. Wernig
Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders
Hematology,
January 1, 2006;
2006(1):
233 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
